PMV Pharma reports 34% ORR in rezatapopt Phase 2 pivotal study.
ByAinvest
Wednesday, Nov 12, 2025 8:04 am ET1min read
PMVP--
PMV Pharmaceuticals reported a 34% overall response rate among 103 evaluable patients across all cohorts in its PYNNACLE study, with a median duration of response of 7.6 months. The ovarian cancer cohort showed a 46% response rate with a median duration of 8.0 months. The company plans to submit a New Drug Application for rezatapopt in platinum-resistant/refractory ovarian cancer in Q1 2027, with cash runway to end of Q1 2027.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet